protein
AMPK
Entity Detail — Knowledge Graph Node
Understanding Entity Pages
This page aggregates everything SciDEX knows about AMPK: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
4730Connections
6Hypotheses
10Analyses
50Outgoing
50Incoming
10Experiments
10Debates
Summary
AMPK is a protein involved in neurodegeneration research. Key relationships include: activates, associated with, interacts with. Associated with AD, ALI, ALS. Connected to 2284 entities in the SciDEX knowledge graph.
AI-generated illustration · click image to enlarge
Regenerate portrait ↻
🔬
Protein Info
| Gene Symbol | AMPK |
| Function | - Modulates neurotransmitter release |
| Pathways | AGING, Autophagy, Mitochondrial Biogenesis, Mitophagy |
| GeneCards | AMPK |
| Human Protein Atlas | AMPK |
| [mTOR](/entities/mtor) | Inhibition of mTORC1 signaling |
| ULK1 | Initiation of autophagy |
| PGC-1α | Mitochondrial biogenesis |
| ACC | Fatty acid oxidation |
| Associated Diseases | AD, Aging, ALI, Als, Alzheimer |
| Known Drugs/Compounds | 17β-estradiol, acteoside, Aloe-emodin, Alpha-Ketoglutarate, BAICALEIN, BERBERINE |
| Interactions | 4E-BP1, 6-OHDA, ABCA1, ABCA7, ABCD3, ABCG1 |
| KG Connections | 4724 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Wiki Pages (15)
Knowledge base pages for this entity
Canonical Page
→
AMPK (AMP-Activated Protein Kinase)
entity · 1068 wordsAMPK Signaling Pathway
mechanism · 3031 wordsAMPK Signaling in Neurodegeneration
mechanism · 1962 wordsPRKAA2 (AMPKα2) — AMP-Activated Protein Kinase Catalytic Subunit Alpha 2
gene · 1883 wordsAMPK Activators for Neurodegeneration
therapeutic · 1869 wordsAD AMPK Activator and Energy Metabolism Companies
company · 1699 wordsPathway Diagram
graph TD
subgraph Signaling["Signaling"]
AMPK["AMPK"] -->|"activates"| ULK1["ULK1"]
AMPK["AMPK"] -->|"activates"| AUTOPHAGY["AUTOPHAGY"]
AMPK["AMPK"] -->|"regulates"| ULK1_1["ULK1"]
AMPK["AMPK"] -->|"regulates"| Autophagy["Autophagy"]
AMPK["AMPK"] -->|"activates"| Cancer["Cancer"]
AMPK["AMPK"] -->|"activates"| Tumor["Tumor"]
AMPK["AMPK"] -->|"activates"| Glycolysis["Glycolysis"]
AMPK["AMPK"] -->|"activates"| Mtor["Mtor"]
SIRT1["SIRT1"] -->|"activates"| AMPK["AMPK"]
PI3K["PI3K"] -->|"activates"| AMPK["AMPK"]
TNF["TNF"] -->|"activates"| AMPK["AMPK"]
PINK1["PINK1"] -->|"activates"| AMPK["AMPK"]
AUTOPHAGY_2["AUTOPHAGY"] -->|"activates"| AMPK["AMPK"]
INFLAMMATION["INFLAMMATION"] -->|"activates"| AMPK["AMPK"]
end
subgraph Therapeutic["Therapeutic"]
AMPK["AMPK"] -->|"therapeutic target"| Als["Als"]
end
style AMPK fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
style ULK1 fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style AUTOPHAGY fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style ULK1_1 fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Cancer fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Tumor fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Glycolysis fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Mtor fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style SIRT1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style PI3K fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style TNF fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style PINK1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style AUTOPHAGY_2 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style INFLAMMATION fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0Outgoing (3311)
| Target | Relation | Type | Str |
|---|---|---|---|
| Nf-Κb | activates | pathway | 1.00 |
| Cancer | therapeutic_target | disease | 1.00 |
| Aging | activates | disease | 1.00 |
| Alzheimer | activates | disease | 1.00 |
| Autophagy | therapeutic_target | pathway | 1.00 |
| Neurodegeneration | activates | disease | 1.00 |
| Als | therapeutic_target | disease | 1.00 |
| Als | regulates | disease | 1.00 |
| Inflammation | activates | disease | 1.00 |
| Apoptosis | activates | pathway | 1.00 |
| Mtor | therapeutic_target | pathway | 1.00 |
| MTOR | activates | gene | 1.00 |
| Als | inhibits | disease | 1.00 |
| Fibrosis | activates | disease | 1.00 |
| Glycolysis | activates | pathway | 1.00 |
| Mtor | activates | pathway | 1.00 |
| Als | activates | disease | 1.00 |
| Autophagy | activates | pathway | 1.00 |
| Tumor | activates | disease | 1.00 |
| Neuroinflammation | activates | disease | 1.00 |
| NEURODEGENERATION | associated_with | gene | 1.00 |
| Ferroptosis | activates | pathway | 1.00 |
| Autophagy | regulates | pathway | 1.00 |
| Oxidative Stress | activates | pathway | 1.00 |
| Aging | therapeutic_target | disease | 1.00 |
| Mitophagy | activates | pathway | 1.00 |
| ULK1 | regulates | protein | 1.00 |
| Insulin Resistance | activates | disease | 1.00 |
| ULK1 | activates | protein | 1.00 |
| AUTOPHAGY | activates | pathway | 1.00 |
| Cancer | activates | disease | 1.00 |
| Differentiation | activates | pathway | 1.00 |
| CANCER | regulates | gene | 1.00 |
| Osteoarthritis | activates | disease | 1.00 |
| AMYLOID | associated_with | protein | 1.00 |
| Tumor | therapeutic_target | disease | 1.00 |
| Ampk Signaling | activates | pathway | 1.00 |
| Inflammation | therapeutic_target | disease | 1.00 |
| NF-KB | associated_with | protein | 1.00 |
| CANCER | targets | gene | 1.00 |
| Inflammation | regulates | disease | 1.00 |
| Mtor | regulates | pathway | 1.00 |
| MTOR | targets | gene | 1.00 |
| MTOR | associated_with | gene | 1.00 |
| Diabetes | activates | disease | 1.00 |
| Obesity | activates | disease | 1.00 |
| NF-ΚB | activates | gene | 1.00 |
| AUTOPHAGY | associated_with | gene | 1.00 |
| Cardiovascular | therapeutic_target | disease | 1.00 |
| Senescence | activates | disease | 1.00 |
Incoming (1419)
| Source | Relation | Type | Str |
|---|---|---|---|
| TNF | activates | gene | 1.00 |
| SIRT1 | activates | gene | 1.00 |
| AUTOPHAGY | activates | gene | 1.00 |
| PI3K | activates | gene | 1.00 |
| PINK1 | activates | gene | 1.00 |
| ROS | activates | gene | 1.00 |
| MITOPHAGY | activates | gene | 1.00 |
| NEURODEGENERATION | activates | gene | 1.00 |
| APOPTOSIS | activates | gene | 1.00 |
| AUTOPHAGY | regulates | gene | 1.00 |
| INFLAMMATION | activates | gene | 1.00 |
| OXIDATIVE STRESS | activates | gene | 1.00 |
| ALZHEIMER'S DISEASE | associated_with | disease | 1.00 |
| PI3K | regulates | gene | 1.00 |
| ATG5 | activates | gene | 1.00 |
| EXERCISE | activates | gene | 1.00 |
| AUTOPHAGY | therapeutic_target | gene | 1.00 |
| ERK | activates | gene | 1.00 |
| INSULIN RESISTANCE | activates | gene | 1.00 |
| BAX | activates | gene | 1.00 |
| lithocholic acid | activates | drug | 0.95 |
| Glycogen Depletion | activates | process | 0.95 |
| Rg1 | activates | compound | 0.95 |
| Metformin | activates | drug | 0.95 |
| exercise | activates | phenotype | 0.95 |
| LUZP1 | activates | protein | 0.95 |
| Leucocyanidin | activates | compound | 0.95 |
| XHP | inhibits | drug | 0.95 |
| Glucose Starvation | activates | process | 0.95 |
| LCA | activates | compound | 0.95 |
| Lithocholic Acid | activates | compound | 0.95 |
| Sodium Butyrate | activates | compound | 0.92 |
| Fluid Flow | activates | mechanism | 0.90 |
| rapamycin | targets | drug | 0.90 |
| Bpa | activates | compound | 0.90 |
| neuronal energy stress | activates | process | 0.90 |
| Pterostilbene | activates | compound | 0.90 |
| FLCN Loss | activates | phenotype | 0.90 |
| Ginsenoside Rk1 | activates | compound | 0.90 |
| LKB1 | activates | protein | 0.90 |
| FLCN | inhibits | gene | 0.90 |
| mitochondrial respiratory chain deficiency | inhibits | phenotype | 0.90 |
| Energy Stress | activates | process | 0.90 |
| lactate production | activates | mechanism | 0.90 |
| Compound C | inhibits | drug | 0.90 |
| PS-NPs | activates | drug | 0.90 |
| AKT | associated_with | gene | 0.90 |
| sulforaphane | activates | drug | 0.90 |
| Qigui Jiangzhi Formula | upregulates | drug | 0.90 |
| Calorie Restriction | activates | process | 0.90 |
Targeting Hypotheses (6)
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| AMPK hypersensitivity in astrocytes creates enhanced mitocho | 0.822 | neurodegeneration | Mitochondrial transfer between astrocyte |
| Closed-loop tACS targeting entorhinal cortex layer II SST in | 0.784 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Neuronal AMPK Restoration (H1): Direct Reversibility Test | 0.680 | neurodegeneration | Does restoring neuronal AMPK activity re |
| AMPK Activation to Restore Autophagy and Clear α-Synuclein A | 0.559 | neurodegeneration | Does RGS6 upregulation or D2 autorecepto |
| Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis | 0.000 | developmental neurobiology | Do perinatal immune challenges create pe |
| Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis | 0.000 | developmental neurobiology | Do perinatal immune challenges create pe |
Mentioning Analyses (10)
Scientific analyses that reference this entity
Does restoring neuronal AMPK activity reverse microglial inflammation in vivo?
neurodegeneration | 2026-04-25 | 7 hypotheses Top: 0.780
Why does Metformin fail to delay CJD progression despite improving anti-aging ha
neurodegeneration | 2026-04-14 | 0 hypotheses
What neural circuits encode and maintain multi-generational migratory route memo
spatial memory | 2026-04-08 | 0 hypotheses
Epigenetic reprogramming in aging neurons
neurodegeneration | 2026-04-04 | 9 hypotheses Top: 0.969
How do neurodegeneration gene expression patterns in SEA-AD differ from other po
neurodegeneration | 2026-04-04 | 2 hypotheses Top: 0.564
Experiments (10)
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD | exploratory | Parkinson's disease | 0.900 | 0.00 | iPSC-derived dopaminergic neur | proposed | N/A |
| Proposed experiment from debate on Astrocytes adopt A1 (neurotoxic) an | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | completed | $100,000 |
| Metabolic Pathway-Targeted Therapy in ALS | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neur | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Related Papers (20)
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892] | Wang Y, An H, Liu T, Qin C, Sesaki H, Gu | Cell Rep | 2019 | 1 |
| AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310] | Song X, Zhu S, Chen P, Hou W, Wen Q, Liu | Curr Biol | 2018 | 1 |
| Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuro [PMID:26121488] | Hang L, Thundyil J, Lim KL | Ann N Y Acad Sci | 2015 | 1 |
| AMPKα1 Deficiency in Macrophages Impairs Tendon Regeneration and Tendon Stem Cel [PMID:41694579] | Zhu L, Wang Y, Shi X, Yu M, Cai X, Chen | International journal of biolo | 2026 | 0 |
| Single-cell transcriptome analysis reveals a cellular immune response in common [PMID:41692207] | Shi X, Ji G, Liu D, Zhao T, Tian S, Li S | International journal of biolo | 2026 | 0 |
| Farrerol ameliorates hepatic insulin resistance via AMPKα1/mTOR/SREBP-1 pathway: [PMID:41702183] | Li Y, Feng X, Zheng L | Tissue & cell | 2026 | 0 |
| Integrative SMR prioritizes oxidative stress-related regulatory genes for Alzhei [PMID:41844011] | Wu L, Dong YT, Mu X, Luo X, Chen ZJ | J Prev Alzheimers Dis | 2026 | 0 |
| Integration proteomics analysis to identify AMPK as key target pathways of TCM f [PMID:41788172] | Chen YJ, Ning DS, Wang CC, Zhao HW, Wang | Journal of traditional and com | 2026 | 0 |
| Baicalein limits subchondral bone lesions via AMPKα/BECN1 activation in osteoart [PMID:41791307] | Zhai Y, Zhou P, Dan L, Ma M, Liu B, Zhan | International immunopharmacolo | 2026 | 0 |
| Integrative SMR prioritizes oxidative stress-related regulatory genes for Alzhei [PMID:41844011] | Wu L, Dong YT, Mu X, Luo X, Chen ZJ | The journal of prevention of A | 2026 | 0 |
| The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] | Dai L, Wang J, Meng L, Zhang X, Xiao T, | PLoS biology | 2025 | 0 |
| An ESIPT + AIE based dual-response fluorescent probe for continuous detection of [PMID:38901234] | ["Zhao J", "Dai C", "Gu B", "Wei M"] | Spectrochimica acta. Part A, M | 2024 | 0 |
| Assessment of the Spatial Distribution of Moisture Content in Granular Material [PMID:31234567] | ["Porzuczek J"] | Sensors (Basel, Switzerland) | 2024 | 0 |
| Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-80 [PMID:39309511] | Li B, Xiao Q, Zhao H, Zhang J, Yang C, Z | Acta pharmaceutica Sinica. B | 2024 | 0 |
| Retracted: Ginsenoside Rg1 Ameliorates Acute Renal Ischemia/Reperfusion Injury v [PMID:38234567] | ["Longevity O"] | Oxidative medicine and cellula | 2024 | 0 |
| Optimal Control with RdCVFL for Degenerating Photoreceptors. [PMID:38345678] | ["Wifvat K", "Camacho E", "Kawski M", "L | Bulletin of mathematical biolo | 2024 | 0 |
| Protective and Detoxifying Effects of Resveratrol on Zearalenone-Mediated Toxici [PMID:39456789] | ["Lv Q", "Xu W", "Yang F", "Li J", "Wei | International journal of molec | 2024 | 0 |
| Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1 [PMID:38953310] | Choi EJ, Oh HT, Lee SH, Zhang CS, Li M, | Autophagy | 2024 | 0 |
Debates (10)
Multi-agent debates referencing this entity
Does restoring neuronal AMPK activity reverse microglial inflammation in vivo?
closed · Rounds: 4 · Score: 0.77 · 2026-04-25
Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and infla
closed · Rounds: 4 · Score: 0.68 · 2026-04-16
Epigenetic reprogramming in aging neurons
closed · Rounds: 4 · Score: 0.95 · 2026-04-10
The paper describes memory-based migration routes maintained across generations
closed · Rounds: 4 · Score: 0.95 · 2026-04-09
Sleep disruption as cause and consequence of neurodegeneration
closed · Rounds: 4 · Score: 0.91 · 2026-04-06
Mitochondrial transfer between astrocytes and neurons
closed · Rounds: 4 · Score: 0.95 · 2026-04-06
How do neurodegeneration gene expression patterns in SEA-AD differ from other po
closed · Rounds: 4 · Score: 0.94 · 2026-04-04
What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc
closed · Rounds: 4 · Score: 0.90 · 2026-04-03
How does metabolic reprogramming (glucose metabolism shifts, brain insulin resis
closed · Rounds: 4 · Score: 0.73 · 2026-04-02
What are the mechanisms underlying what are the mechanisms by which gut microbio
closed · Rounds: 4 · Score: 0.95 · 2026-04-01
Related Research
Hypotheses and analyses mentioning AMPK in their description or question text